2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Pt w/ oGVHD

Launched by UNIVERSITY OF MARYLAND, BALTIMORE · Jun 22, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "2177GCCC:ID'Ing tx Targets and Biomarkers for Ocular Surface Disease in Patients with Ocular Graft-versus-Host Disease (oGVHD)," is aimed at understanding the changes happening on the eye's surface in cancer patients who have a condition known as oGVHD, which can cause dry eye disease. The researchers want to learn more about the immune system's role in this condition to improve treatment options for those affected.

To be eligible for this trial, participants must be at least 18 years old and visit specific eye clinics associated with the University of Maryland. They should be able to understand and sign a consent form, agreeing to take part in the study. Unfortunately, those who have had certain eye surgeries or belong to vulnerable groups like children or prisoners cannot participate. If you join the study, you can expect to undergo assessments to help the researchers gather important information about your eye health and the effects of oGVHD. This research could lead to better management and treatment strategies for individuals suffering from these eye conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (≥ 18 years of age) who visit the Eye clinic either in the UMGCCC within the UMD Hospital or the UMD Faculty Physicians Ophthalmology Practice at the UMD Professional Building or satellite locations for initial visits or established visits.
• • The patient must be able to understand and sign and date the informed consent form approved by the IRB.
• Exclusion Criteria:
• • Vulnerable populations: neonates, children, prisoners, institutionalized individuals.
• • Inability or refusal to provide informed consent.
• • History of ocular surgery (except refractive surgery or cataract surgery)